Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;88(9):3947-3949.
doi: 10.1111/bcp.15359. Epub 2022 May 8.

Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?

Luca D'andrea  1 , Marina Montemagni  2 , Giuseppe Celenza  3 , Roberto Iorio  3 , Ciro Costagliola  2
Affiliations

Is it time for a moratorium on the use of benzalkonium chloride in eyedrops?

Luca D'andrea et al. Br J Clin Pharmacol. 2022 Sep.
No abstract available

Keywords: BAC; OSD; benzalkonium chloride; glaucoma; neuroinflammation; toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Detrimental effects of benzalkonium chloride on the ocular surface
See this image and copyright information in PMC

References

    1. Steven DW, Alaghband P, Lim KS. Preservatives in glaucoma medication. Br J Ophthalmol. 2018;102(11):1497‐1503. doi:10.1136/bjophthalmol-2017-311544 - DOI - PMC - PubMed
    1. Nakamura T, Yamada M, Teshima M, et al. Electrophysiological characterization of tight junctional pathway of rabbit cornea treated with ophthalmic ingredients. Biol Pharm Bull. 2007;30(12):2360‐2364. doi:10.1248/bpb.30.2360 - DOI - PubMed
    1. Pellinen P, Lokkila J. Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative‐free tafluprost. Ophthalmic Res. 2009;41(2):118‐122. doi:10.1159/000192082 - DOI - PubMed
    1. Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure‐lowering medications. Cornea. 2010;29(6):618‐621. doi:10.1097/ico.0b013e3181c325b2 - DOI - PubMed
    1. Rossi GC, Pasinetti GM, Scudeller L, Raimondi M, Lanteri S, Bianchi PE. Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients. Eur J Ophthalmol. 2013;23(3):296‐302. doi:10.5301/ejo.5000220 - DOI - PubMed

MeSH terms